ResMed Inc. (LON: 0KW4)
London
· Delayed Price · Currency is GBP · Price in USD
244.85
-1.68 (-0.68%)
Jan 23, 2025, 2:44 PM BST
ResMed Revenue
ResMed had revenue of $1.22B USD in the quarter ending September 30, 2024, with 11.08% growth. This brings the company's revenue in the last twelve months to $4.81B, up 9.88% year-over-year. In the fiscal year ending June 30, 2024, ResMed had annual revenue of $4.69B with 10.95% growth.
Revenue (ttm)
$4.81B
Revenue Growth
+9.88%
P/S Ratio
n/a
Revenue / Employee
$481.71K
Employees
9,980
Market Cap
29.49B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
ResMed News
- 10 days ago - Top 50 High Quality Dividend Growth Stocks - January 2025 - Seeking Alpha
- 12 days ago - Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
- 13 days ago - ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 - GlobeNewsWire
- 16 days ago - ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 20 days ago - My Top 15 High Growth Dividend Stocks For January 2025 - Seeking Alpha
- 4 weeks ago - Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound - Investopedia
- 4 weeks ago - Top Stock Movers Now: Broadcom, AMD, ResMed, and More - Investopedia
- 4 weeks ago - ResMed, Inspire Medical fall after Lilly's Zepbound gains sleep apnea indication - Seeking Alpha